ClinicalTrials.gg
CompletedNCT01588782Updated Nov 27, 2012

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men

A Phase 1 interventional study of Period 1: Abiraterone and Period 2: Abiraterone/Ketoconazole in Healthy Volunteers, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and potential for drug-drug interactions when a strong inhibitor of CYP3A4 (ie, ketoconazole) is co-administered with abiraterone acetate in healthy adult men.

Read the detailed description

This is a non-randomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), 2-period, sequential-design, drug-drug interaction study of abiraterone acetate and ketoconazole in approximately 20 healthy adult men. This study will consist of a screening period followed by an open-label treatment phase consisting of 2 treatment periods. Successive drug administration will be separated by a washout period of at least 10 days. All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected at each treatment period as detailed in the protocol. Safety will be monitored continuously from the time of informed consent signing until the end of the study.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • Pharmacology
  • Pharmacokinetics
  • Pharmacodynamics
  • Drug-drug interactions
  • CYP3A4
  • Abiraterone acetate
  • JNJ-589485
  • JNJ-212082
  • Ketoconazole
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18 and 30 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate

    All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.

    Drug: Period 1: Abiraterone · Drug: Period 2: Abiraterone/Ketoconazole

Interventions

  • 1000 mg abiraterone acetate tablet administered orally on Day 1

  • DrugPeriod 2: Abiraterone/Ketoconazole

    Drug pages: Abiraterone · Ketoconazole

    400 mg ketoconazole tablets administered orally on Days 11 to 16

  • DrugPeriod 2: Abiraterone/Ketoconazole

    Drug pages: Abiraterone · Ketoconazole

    1000 mg abiraterone acetate tablet administered orally on Day 14

06

What researchers measure

Primary outcomes

  1. Mean plasma concentrations of abiraterone

    Time frame: Up to Day 17

  2. Mean plasma concentrations of ketoconazole

    Time frame: Up to Day 14

  3. Maximum plasma concentrations of abiraterone

    Time frame: Up to Day 17

  4. Time to reach the maximum plasma concentration of abiraterone

    Time frame: Up to Day 17

  5. Area under the plasma concentration-time curve from time 0 to time to the last quantifiable concentration of abiraterone

    Time frame: Up to Day 17

  6. Area under the plasma concentration-time curve from time 0 to infinite time of abiraterone

    Time frame: Up to Day 17

  7. Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone

    Time frame: Up to Day 17

  8. First-order rate constant associated with the terminal portion of the curve of abiraterone

    Time frame: Up to Day 17

  9. Time to last quantifiable plasma concentration of abiraterone

    Time frame: Up to Day 17

  10. Percentage of area under the plasma concentration-time curve from time 0 to infinite time obtained by extrapolation of abiraterone

    Time frame: Up to Day 17

Secondary outcomes

  1. The number of participants affected by an adverse event

    Time frame: Up to end of study or early withdrawal

07

Study locations

1 site
  • Merksem, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2012
First posted
May 1, 2012
Start
Jan 2012
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01588782
Responsible party
Sponsor
First posted
May 1, 2012
Start date
Jan 2012
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Nov 27, 2012

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone · Ketoconazole

Start the discussion